
Over the last 7 days, the Clinical Research and Equipment industry has dropped 4.4%, driven by a pullback from HeXun Biosciences of 6.1%. In contrast, EirGenix has gained 5.5%. Overall the industry is down 5.5% in 12 months.
Has the Taiwanese Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 19 Jun 2026 | NT$31.9b | NT$2.7b | -NT$747,832,000.00 | 20.7x | -42.6x | 12x |
| Sun, 17 May 2026 | NT$32.7b | NT$2.7b | -NT$746,869,000.00 | 21.3x | -43.7x | 12.3x |
| Tue, 14 Apr 2026 | NT$32.0b | NT$2.5b | -NT$767,980,000.00 | 21.6x | -41.7x | 12.8x |
| Thu, 12 Mar 2026 | NT$31.9b | NT$2.4b | -NT$693,178,000.00 | 19.1x | -46.1x | 13.1x |
| Sat, 07 Feb 2026 | NT$33.3b | NT$2.4b | -NT$689,929,000.00 | 24x | -48.2x | 13.7x |
| Mon, 05 Jan 2026 | NT$34.0b | NT$2.4b | -NT$689,929,000.00 | 25.8x | -49.3x | 14x |
| Wed, 03 Dec 2025 | NT$38.0b | NT$2.4b | -NT$670,921,000.00 | 19.6x | -56.7x | 15.5x |
| Fri, 31 Oct 2025 | NT$35.1b | NT$2.5b | -NT$870,437,000.00 | 18.3x | -40.4x | 14.3x |
| Sun, 28 Sep 2025 | NT$36.9b | NT$2.5b | -NT$870,437,000.00 | 19.8x | -42.4x | 15x |
| Tue, 26 Aug 2025 | NT$35.3b | NT$2.5b | -NT$819,216,000.00 | 20.5x | -43.1x | 14.4x |
| Thu, 24 Jul 2025 | NT$34.8b | NT$2.5b | -NT$600,003,000.00 | 21.9x | -57.9x | 14.1x |
| Sat, 21 Jun 2025 | NT$34.3b | NT$2.5b | -NT$600,003,000.00 | 22.6x | -57.1x | 13.9x |
| Mon, 19 May 2025 | NT$32.0b | NT$2.5b | -NT$604,301,000.00 | 23.4x | -52.9x | 13x |
| Wed, 16 Apr 2025 | NT$31.9b | NT$2.5b | -NT$540,128,000.00 | 24.5x | -59x | 12.9x |
| Fri, 14 Mar 2025 | NT$35.7b | NT$2.6b | -NT$851,729,000.00 | 24.7x | -41.9x | 14x |
| Sun, 09 Feb 2025 | NT$38.0b | NT$2.6b | -NT$854,432,000.00 | 23.9x | -44.4x | 14.8x |
| Tue, 07 Jan 2025 | NT$34.9b | NT$2.6b | -NT$854,432,000.00 | 22.8x | -40.8x | 13.6x |
| Thu, 05 Dec 2024 | NT$41.7b | NT$2.6b | -NT$854,432,000.00 | 24.1x | -48.8x | 16.3x |
| Sat, 02 Nov 2024 | NT$42.2b | NT$2.5b | -NT$712,402,000.00 | 24.1x | -59.2x | 16.8x |
| Mon, 30 Sep 2024 | NT$41.7b | NT$2.3b | -NT$836,610,000.00 | 22.5x | -49.8x | 18.3x |
| Wed, 28 Aug 2024 | NT$41.0b | NT$2.3b | -NT$836,610,000.00 | 22.6x | -49x | 18x |
| Fri, 26 Jul 2024 | NT$43.1b | NT$2.1b | -NT$797,765,000.00 | 33.3x | -54x | 20.2x |
| Sun, 23 Jun 2024 | NT$42.5b | NT$2.1b | -NT$797,765,000.00 | 34.3x | -53.2x | 19.9x |
| Tue, 21 May 2024 | NT$40.5b | NT$2.1b | -NT$797,765,000.00 | 32.4x | -50.7x | 19x |
| Thu, 18 Apr 2024 | NT$39.4b | NT$2.1b | -NT$923,759,000.00 | 30.3x | -42.7x | 18.7x |
| Sat, 16 Mar 2024 | NT$40.2b | NT$2.1b | -NT$611,249,000.00 | 32.4x | -65.7x | 19.5x |
| Mon, 12 Feb 2024 | NT$43.0b | NT$2.1b | -NT$610,218,000.00 | 32.4x | -70.4x | 20.7x |
| Wed, 10 Jan 2024 | NT$45.6b | NT$2.1b | -NT$610,218,000.00 | 34.2x | -74.7x | 22x |
| Fri, 08 Dec 2023 | NT$48.5b | NT$2.1b | -NT$610,218,000.00 | 33.6x | -79.5x | 23.4x |
| Sun, 05 Nov 2023 | NT$48.5b | NT$2.2b | -NT$497,769,000.00 | 31.8x | -97.4x | 21.8x |
| Tue, 03 Oct 2023 | NT$48.9b | NT$2.2b | -NT$497,769,000.00 | 31.2x | -98.3x | 22x |
| Thu, 31 Aug 2023 | NT$44.0b | NT$2.2b | -NT$497,769,000.00 | 31.5x | -88.3x | 19.8x |
| Sat, 29 Jul 2023 | NT$47.5b | NT$2.5b | -NT$274,767,000.00 | 42.9x | -172.9x | 19.4x |
| Mon, 26 Jun 2023 | NT$48.4b | NT$2.5b | -NT$274,767,000.00 | 43.2x | -176.1x | 19.7x |
-176.1x
How does Taiwanese Clinical Research and Equipment compare with similar industries?
| TW Market | 7.79% | |
| Healthcare | 7.25% | |
| Life Sciences | 2.83% | |
| Clinical Research and Equipment | 2.83% | |
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 6589 EirGenix | NT$46.25 | 5.5% +NT$726.4m | -22.4% | PS12.4x | |
| 6891 Locus Cell | NT$45.90 | 2.3% +NT$210.0m | 117.0% | PS720.8x | |
| 6848 RBC Bioscience | NT$20.30 | 3.0% +NT$8.6m | 24.1% | PE12.3x | |
| 4133 Abnova (Taiwan) | NT$20.70 | 0.5% +NT$6.1m | -23.0% | PE652.8x |